Scant data are available on MMR complex proteins in high-grade gliomas [16], and deficit of expression of MSH6 might contribute to alkylating agent resistance and recurrence [17,18]; despite that, the role of MMRd in terms of survival in this setting of patients seems unclear. The gene discussed is MSH6; the disease is central nervous system cancer.